NLS Pharmaceutics AG (NLSP)
After hours:
| Previous Close | 0.5872 |
| Open | 0.5899 |
| Bid | 0.5310 x 1000 |
| Ask | 0.5873 x 1800 |
| Day's Range | 0.5300 - 0.5899 |
| 52 Week Range | 0.4600 - 3.7200 |
| Volume | |
| Avg. Volume | 53,880 |
| Market Cap | 10.379M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0040 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
- ACCESSWIRE
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.
- ACCESSWIRE
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Chad C.
- ACCESSWIRE
NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment of Narcolepsy
Additionally, the Company reports that enrollment and ongoing patient dosing in its OLE study for Quilience monotherapy continue to exhibit favorable trends."With patient enrollment now complete, we remain on track to report top-line efficacy and safety results from our Phase 2a narcolepsy trial for Quilience during the ESRS conference in late September," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
